IP Library Granted Patent US 8,722,895
Granted Patent B2
US 8,722,895 · App. 13/859,574 · Granted May 13, 2014

Prolyl hydroxylase inhibitors and method of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,895
App. No.
13/859,574
Granted
May 13, 2014
Kind
B2
Abstract

The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

Claims (30)

1. A compound having the formula:

wherein R 2 is chosen from:

i) —OR 6 ; or

ii) —NR 7a R 7b ;

R 6 is hydrogen, methyl or ethyl;

R 7a and R 7b are independently hydrogen, methyl or ethyl; or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein R 2 is —OR 6 .

3. The compound according to claim 2 , wherein R 6 is hydrogen.

4. The compound according to claim 2 , wherein R 6 is methyl.

5. The compound according to claim 1 , wherein R 2 is —NR 7a R 7b .

6. The compound according to claim 5 , wherein R 7a and R 7b are each independently hydrogen or methyl.

7. The compound according to claim 6 , wherein R 2 is —NH 2 .

8. The compound {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid.

9. A composition, comprising:

A) a compound having the formula:

wherein R 2 is chosen from:

i) —OR 6 ; or

ii) —NR 7a R 7b ;

R 6 is hydrogen, methyl or ethyl;

R 7a and R 7b are independently hydrogen, methyl or ethyl; or a pharmaceutically acceptable salt thereof; and

B) one or more pharmaceutically acceptable ingredients.

10. The composition according to claim 9 , wherein R 2 is —OR 6 .

11. The composition according to claim 10 , wherein R 6 is hydrogen.

12. The composition according to claim 10 , wherein R 6 is methyl.

13. The composition according to claim 9 , wherein R 2 is —NR 7a R 7b .

14. The composition according to claim 13 , wherein R 7a and R 7b are each independently hydrogen or methyl.

15. The composition according to claim 14 , wherein R 2 is —NH 2 .

16. The composition according to claim 9 , wherein the compound is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, or a pharmaceutically acceptable salt thereof.

17. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

Assignments (5)
SECURITY INTEREST Recorded Jan 29, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 066377/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2022
From: THE PROCTER & GAMBLE COMPANY
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 059500/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2022
From: KAWAMOTO, RICHARD MASARU
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 059398/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2022
From: WU, SHENGDE; WARSHAKOON, NAMAL C.; EVDOKIMOV, ARTEM G.; GREIS, KENNETH D.; BOYER, ANGELIQUE SUN
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 059398/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2022
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 059399/0199 →